Katsunori Ikewaki

Dr. Katsunori Ikewaki


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
YEYasuhiro Endo
Yasuhiro Endo
MFMasanori Fujita
Masanori Fujita
KIKatsunori Ikewaki
Katsunori Ikewaki
Cardiovascular disease (CVD) is the leading cause of death in Western countries. A low HDL-C is associated with the development of CVD. However, recent epidemiology studies have shown U-shaped curves between HDL-C and CVD mortality, with paradoxically increased CVD mortality in patients with extremely high HDL-C levels. Furthermore, HDL-C raising therapy using nicotinic acids or CETP inhibitors mostly failed to reduce CVD events. Based on this background, HDL functions rather than HDL-C could be a novel biomarker; research on the clinical utility of HDL functionality is ongoing. In this review, we summarize the current status of HDL functions and their future perspectives from the findings of basic research and clinical trials.

1 January 2024 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
YEYasuhiro Endo
Yasuhiro Endo
KSKei Sasaki
Kei Sasaki
KIKatsunori Ikewaki
Katsunori Ikewaki
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

3 December 2022 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
YEYasuhiro Endo
Yasuhiro Endo
MFMasanori Fujita
Masanori Fujita
KIKatsunori Ikewaki
Katsunori Ikewaki
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.